Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1656 1693 1754
This examiner grants 46% of resolved cases
Marsha M. Tsay has resolved 847 cases in Art Unit 1656 of Tech Center 1700. The allowance rate is 45.7%, and the median time to allowance is 1330 days. This data reflects a difficult and lengthy prosecution process for the 847 cases resolved. The 1330-day median pendency is a significant factor for applicants to consider when filing in this unit.
The interview lift of 52.7% is a vital metric for applicants. It indicates that an interview can more than double the probability of success relative to the 45.7% baseline allowance rate. Given the 847 cases resolved, this 52.7% lift is a well-established trend that practitioners should leverage to overcome the 1330-day median pendency. Direct engagement is highly recommended.
In Tech Center 1700, the 45.7% allowance rate suggests a high threshold for patentability. However, the 52.7% interview lift shows that the examiner is very receptive to applicant arguments. The 1330-day median to allowance provides a realistic timeline for the 847 cases resolved by this examiner in Art Unit 1656.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19246328 | COMPOSITIONS AND METHODS FOR LOGIC-GATED PROFILING OF BIOLOGIC ACTIVITY | Non-Final OA | Georgia Tech Research Corporation |
| 17846696 | COMPOSITIONS COMPRISING ENZYMES | Non-Final OA | The Procter & Gamble Company |
| 18855898 | EQUOL MANUFACTURING METHOD | Non-Final OA | Daicel Corporation |
| 18452884 | CYCLIC LIPOPEPTIDE-PRODUCING MICROBIAL STRAIN AND METHOD FOR PRODUCING CYCLIC LIPOPEPTIDE | Final Rejection | KANEKA CORPORATION |
| 17849327 | Methods and Compositions for Producing a Heterologous Antiviral Compound in a Host Cell | Final Rejection | The Regents of the University of California |
| 18036695 | MICROBIAL PRODUCTION OF TITIN FIBERS WITH EXCEPTIONAL MECHANICAL PERFORMANCE | Non-Final OA | Washington University |
| 17436338 | NON-VIRAL MODIFICATION OF MESENCHYMAL STEM CELLS | Non-Final OA | NATIONAL UNIVERSITY OF SINGAPORE |
| 17938752 | De novo designed protein homodimers containing tunable symmetric pockets | Non-Final OA | University of Washington |
| 18255869 | METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION | Non-Final OA | PFIZER INC. |
| 17021319 | NANOLITER-SCALE SAMPLE PROCESSING AND MASS SPECTROMETRY ACQUISITION METHOD FOR SINGLE CELL PROTEOMICS | Final Rejection | BATTELLE MEMORIAL INSTITUTE |
| 18917399 | NUCLEOSIDE TRIPHOSPHATE TRANSPORTER AND USES THEREOF | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18723211 | REDUCTION OF RESIDUAL DNA IN MICROBIAL FERMENTATION PRODUCTS | Final Rejection | Novozymes A/S |
| 17909908 | MECHANISTIC BIOMARKER FOR PREDICTING THE SURVIVAL OF PANCREATIC CANCER PATIENTS | Final Rejection | Oregon Health & Science University |
| 17908427 | PROTEINS WITH PREDICTABLE LIQUID-LIQUID PHASE SEPARATION | Final Rejection | Duke University |
| 18817164 | Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances | Non-Final OA | Genzyme Corporation |
| 17995624 | GENE EXPRESSION SYSTEM FOR RAPID CONSTRUCTION OF MULTIPLE-GENE PATHWAY IN OLEAGINOUS YEASTS | Final Rejection | WASHINGTON STATE UNIVERSITY |
| 18020843 | REAL-TIME CELLULAR THERMAL SHIFT ASSAY (RT-CETSA) FOR RESEARCH AND DRUG DISCOVERY | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 17416814 | URINE STABILIZATION | Non-Final OA | QIAGEN GmbH |
| 17782684 | Method for Manufacturing a Fibrinogen Preparation | Final Rejection | Biotest AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy